Here is the detailed overview of the combination tablet:
Tenofovir + Lamivudine + Dolutegravir
with icons and clear formatting.
💊 Tenofovir (300 mg) + Lamivudine (300 mg) + Dolutegravir (50 mg) Tablet
🧪 Nature / Drug Class
🔹 Tenofovir (TDF) – NRTI (Nucleotide Reverse Transcriptase Inhibitor)
🔹 Lamivudine (3TC) – NRTI (Nucleoside Reverse Transcriptase Inhibitor)
🔹 Dolutegravir (DTG) – INSTI (Integrase Strand Transfer Inhibitor)
🩺 Purpose / Indications
✅ Used in the treatment of HIV-1 infection, especially:
- 🌍 As part of first-line ART in adults and adolescents
- 🔁 Also used in post-exposure prophylaxis (PEP) protocols
- 🛡️ Effective for patients new to ART or needing switch from older regimens
⚙️ Advantages
✔️ Once-daily fixed-dose – improves adherence
✔️ High barrier to resistance (especially due to dolutegravir)
✔️ Suitable for co-infection with Hepatitis B (Tenofovir + Lamivudine active against HBV)
✔️ Preferred first-line ART regimen by WHO and national HIV programs
📦 Common Packaging
📦 Tablet contains:
- 🧪 Tenofovir Disoproxil Fumarate: 300 mg
- 🧪 Lamivudine: 300 mg
- 🧪 Dolutegravir: 50 mg
💊 Usually packed in bottles of 30 tablets (1-month supply)
⚠️ Patient Advice / Precautions
🕐 Take once daily, with or without food
📉 Regular monitoring:
- 🔬 HIV viral load
- 🧪 CD4 count
- 🧫 Liver & kidney function
🧬 Do not skip doses – risk of resistance
⚠️ Watch for rare side effects: - 😓 Insomnia or headache (from dolutegravir)
- 🦠 Lactic acidosis signs
🚫 Not for use in patients with severe renal impairment without adjustment
👩🍼 Safe in pregnancy, but must be monitored
🧊 Storage
🌡️ Store at room temperature
🚫 Keep away from heat, moisture, and sunlight
🧒 Keep out of reach of children